Johnson & Johnson (NYSE:JNJ) Posts Quarterly Earnings Results

Key Points

• Johnson & Johnson reported a Q3 EPS of $2.80, exceeding analysts' expectations of $2.78 by $0.02.
• The company also announced a quarterly dividend of $1.30 per share, with a 2.7% dividend yield and an ex-dividend date set for November 25th.
• Analysts have raised price targets for JNJ, with JPMorgan setting a new target of $200.00 and Wells Fargo at $212.00, forecasting a Moderate Buy rating for the stock.

Johnson & Johnson (NYSE:JNJ - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.76 by $0.04, Zacks reports. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.99 billion during the quarter, compared to analyst estimates of $23.73 billion. During the same period last year, the company earned $2.42 earnings per share. The business's revenue for the quarter was up 6.8% on a year-over-year basis. Johnson & Johnson updated its FY 2025 guidance to 10.800-10.900 EPS.

Johnson & Johnson Stock Up 0.1%

NYSE JNJ opened at $190.88 on Tuesday. The business's 50-day moving average is $178.88 and its 200 day moving average is $163.97. The stock has a market capitalization of $459.71 billion, a PE ratio of 20.42, a PEG ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Morgan Stanley lifted their target price on Johnson & Johnson from $176.00 to $178.00 and gave the company an "equal weight" rating in a report on Friday. HSBC boosted their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group set a $198.00 price target on Johnson & Johnson in a report on Friday, October 3rd. Finally, Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $192.94.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently bought and sold shares of JNJ. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Johnson & Johnson by 45.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 552,292 shares of the company's stock worth $84,346,000 after purchasing an additional 172,422 shares during the period. Lazard Asset Management LLC raised its position in shares of Johnson & Johnson by 13.0% in the second quarter. Lazard Asset Management LLC now owns 778,261 shares of the company's stock worth $118,878,000 after buying an additional 89,763 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Johnson & Johnson by 1.7% during the second quarter. California State Teachers Retirement System now owns 3,899,683 shares of the company's stock valued at $595,677,000 after buying an additional 65,322 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Johnson & Johnson by 1.9% in the second quarter. CANADA LIFE ASSURANCE Co now owns 2,950,858 shares of the company's stock worth $451,116,000 after purchasing an additional 54,894 shares during the period. Finally, Engineers Gate Manager LP increased its holdings in Johnson & Johnson by 252.6% in the 2nd quarter. Engineers Gate Manager LP now owns 74,262 shares of the company's stock worth $11,344,000 after acquiring an additional 53,200 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.